Interpace Biosciences Return on Tangible Equity 2010-2023 | IDXG
Current and historical return on tangible equity values for Interpace Biosciences (IDXG) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Interpace Biosciences Return On Tangible Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Tangible Equity | Return on Tangible Equity |
| 2023-12-31 | $0.00B | $-0.06B | 0.00% |
| 2023-09-30 | $-0.00B | $-0.06B | 4.76% |
| 2023-06-30 | $-0.02B | $-0.06B | 25.40% |
| 2023-03-31 | $-0.02B | $-0.06B | 31.62% |
| 2022-12-31 | $-0.02B | $-0.06B | 35.20% |
| 2022-09-30 | $-0.02B | $-0.06B | 41.56% |
| 2022-06-30 | $-0.01B | $-0.06B | 25.11% |
| 2022-03-31 | $-0.01B | $-0.06B | 24.41% |
| 2021-12-31 | $-0.02B | $-0.05B | 29.27% |
| 2021-09-30 | $-0.02B | $-0.06B | 36.36% |
| 2021-06-30 | $-0.02B | $-0.05B | 42.64% |
| 2021-03-31 | $-0.02B | $-0.05B | 52.75% |
| 2020-12-31 | $-0.03B | $-0.05B | 73.17% |
| 2020-09-30 | $-0.03B | $-0.04B | 91.67% |
| 2020-06-30 | $-0.04B | $-0.04B | 116.67% |
| 2020-03-31 | $-0.03B | $-0.03B | 172.15% |
| 2019-12-31 | $-0.03B | $-0.03B | 284.21% |
| 2019-09-30 | $-0.02B | $-0.02B | 1400.00% |
| 2019-06-30 | $-0.02B | $0.00B | -355.56% |
| 2019-03-31 | $-0.01B | $0.01B | -236.36% |
| 2018-12-31 | $-0.01B | $0.00B | -236.36% |
| 2018-09-30 | $-0.01B | $0.01B | -200.00% |
| 2018-06-30 | $-0.01B | $0.01B | -226.09% |
| 2018-03-31 | $-0.02B | $0.01B | -377.78% |
| 2017-12-31 | $-0.01B | $0.01B | -5534023222112865280.00% |
| 2017-09-30 | $-0.00B | $0.00B | 10.81% |
| 2017-06-30 | $-0.01B | $0.00B | 25.64% |
| 2017-03-31 | $-0.00B | $-0.01B | 3.45% |
| 2016-12-31 | $-0.01B | $-0.03B | 23.02% |
| 2016-09-30 | $-0.01B | $-0.04B | 28.78% |
| 2016-06-30 | $-0.01B | $-0.04B | 20.78% |
| 2016-03-31 | $-0.01B | $-0.03B | 30.77% |
| 2015-12-31 | $-0.01B | $-0.03B | 26.67% |
| 2015-09-30 | $-0.02B | $-0.05B | 47.67% |
| 2015-06-30 | $-0.02B | $-0.05B | 67.69% |
| 2015-03-31 | $-0.02B | $-0.05B | 138.46% |
| 2014-12-31 | $-0.02B | $-0.04B | -290.91% |
| 2014-09-30 | $-0.01B | $0.01B | -53.61% |
| 2014-06-30 | $-0.01B | $0.03B | -36.36% |
| 2014-03-31 | $-0.01B | $0.03B | -27.91% |
| 2013-12-31 | $-0.01B | $0.03B | -14.81% |
| 2013-09-30 | $-0.03B | $0.03B | -73.53% |
| 2013-06-30 | $-0.02B | $0.04B | -70.07% |
| 2013-03-31 | $-0.02B | $0.04B | -67.65% |
| 2012-12-31 | $-0.03B | $0.03B | -74.07% |
| 2012-09-30 | $-0.01B | $0.03B | -32.59% |
| 2012-06-30 | $-0.01B | $0.03B | -29.20% |
| 2012-03-31 | $-0.01B | $0.03B | -31.65% |
| 2011-12-31 | $-0.01B | $0.03B | -34.04% |
| 2011-09-30 | $-0.01B | $0.04B | -13.99% |
| 2011-06-30 | $-0.01B | $0.04B | -16.37% |
| 2011-03-31 | $-0.01B | $0.04B | -13.93% |
| 2010-12-31 | $-0.01B | $0.04B | -13.85% |
| 2010-09-30 | $-0.02B | $0.06B | -34.98% |
| 2010-06-30 | $-0.03B | $0.07B | -39.10% |
| 2010-03-31 | $-0.03B | $0.07B | -44.28% |
| 2009-12-31 | $-0.03B | $0.07B | -48.57% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.007B | $0.040B |
| Interpace Biosciences Inc. is enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications. Its clinical services include molecular diagnostic tests, bioinformatics, and pathology services. Pharma services provide pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. Interpace Biosciences Inc., formerly known as INTERPACE DIAGN, is based in PARSIPPANY, NJ. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elevance Health (ELV) | United States | $124.869B | 15.67 |
| Cencora (COR) | United States | $48.051B | 19.18 |
| ICON (ICLR) | Ireland | $25.434B | 24.01 |
| DiDi Global (DIDIY) | China | $24.387B | 0.00 |
| Avantor (AVTR) | United States | $16.238B | 23.94 |
| Viatris (VTRS) | United States | $13.880B | 3.96 |
| CochLear (CHEOY) | $13.776B | 0.00 | |
| Revvity (RVTY) | United States | $12.539B | 21.83 |
| Medpace Holdings (MEDP) | United States | $12.267B | 40.36 |
| Charles River Laboratories (CRL) | United States | $11.798B | 21.51 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $11.548B | 0.00 |
| Natera (NTRA) | United States | $11.205B | 0.00 |
| Solventum (SOLV) | United States | $11.115B | 0.00 |
| HealthEquity (HQY) | United States | $6.886B | 51.45 |
| Bausch + Lomb (BLCO) | Canada | $5.197B | 19.99 |
| Organon (OGN) | United States | $4.742B | 4.59 |
| Doximity (DOCS) | United States | $4.444B | 33.08 |
| PACS (PACS) | United States | $3.713B | 0.00 |
| Sotera Health (SHC) | United States | $3.227B | 15.83 |
| Surgery Partners (SGRY) | United States | $3.108B | 28.88 |
| Progyny (PGNY) | United States | $3.079B | 51.68 |
| GoodRx Holdings (GDRX) | United States | $2.840B | 143.80 |
| Life Times (LTH) | United States | $2.783B | 30.76 |
| Premier (PINC) | United States | $2.511B | 9.19 |
| Teladoc Health (TDOC) | United States | $2.203B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $2.164B | 7.00 |
| Agilon Health (AGL) | United States | $2.055B | 0.00 |
| BrightSpring Health Services (BTSG) | United States | $1.811B | 0.00 |
| Agiliti (AGTI) | United States | $1.368B | 22.33 |
| NovoCure (NVCR) | Jersey | $1.360B | 0.00 |
| Establishment Labs Holdings (ESTA) | $1.331B | 0.00 | |
| Alignment Healthcare (ALHC) | United States | $0.985B | 0.00 |
| Pediatrix Medical (MD) | United States | $0.760B | 7.86 |
| Embecta (EMBC) | United States | $0.594B | 3.92 |
| InnovAge Holding (INNV) | United States | $0.531B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.522B | 0.00 |
| Enhabit (EHAB) | United States | $0.503B | 45.59 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.492B | 0.00 |
| LifeMD (LFMD) | United States | $0.482B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $0.434B | 0.00 |
| Beauty Health (SKIN) | United States | $0.400B | 0.00 |
| CareDx (CDNA) | United States | $0.391B | 0.00 |
| DocGo (DCGO) | United States | $0.376B | 60.17 |
| MultiPlan (MPLN) | United States | $0.371B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.349B | 0.00 |
| ModivCare (MODV) | United States | $0.335B | 4.44 |
| Sharecare (SHCR) | United States | $0.290B | 0.00 |
| GeneDx Holdings (WGS) | United States | $0.289B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.269B | 0.00 |
| Biodesix (BDSX) | United States | $0.142B | 0.00 |
| So-Young (SY) | China | $0.125B | 41.83 |
| Oncology Institute (TOI) | United States | $0.085B | 0.00 |
| Pono Capital Two (PTWO) | United States | $0.078B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.055B | 0.00 |
| NeueHealth (NEUE) | United States | $0.050B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.035B | 0.00 |
| Nutex Health (NUTX) | United States | $0.033B | 0.00 |
| Singular Genomics Systems (OMIC) | United States | $0.030B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.029B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.024B | 0.00 |
| DermTech (DMTK) | United States | $0.021B | 0.00 |
| OncoCyte (OCX) | United States | $0.021B | 0.00 |
| BIMI Holdings (BIMI) | United States | $0.014B | 0.00 |
| Aesthetic Medical Hldngs Group (AIH) | China | $0.013B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.011B | 0.00 | |
| TRxADE HEALTH (MEDS) | United States | $0.009B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.008B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| NewGenIvf Group (NIVF) | Singapore | $0.007B | 0.00 |
| OpGen (OPGN) | United States | $0.007B | 0.00 |
| Assure Holdings (IONM) | United States | $0.005B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| Aclarion (ACON) | United States | $0.002B | 0.00 |